Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Advanced Solid Cancer × Injections × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Leukemia, Myeloid, Acute 19 Advanced Solid Tumors 14 Breast Neoplasms 10 Neoplasms 9 Myelodysplastic Syndromes 9 Prostatic Neoplasms 7 Advanced Solid Tumor 7 Solid Tumor 6 Neoplasm Metastasis 6 Carcinoma, Non-Small-Cell Lung 6 Recurrence 5 Pancreatic Neoplasms 4 Multiple Myeloma 4 Leukemia, Myelomonocytic, Chronic 4 Stomach Neoplasms 3 Solid Tumors 3 Small Cell Lung Carcinoma 3 Ovarian Neoplasms 3 Melanoma 3 Lung Neoplasms 3 Leukemia 3 Carcinoma, Hepatocellular 3 Primary Myelofibrosis 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Nasopharyngeal Carcinoma 2 Lymphoma, T-Cell, Peripheral 2 Lymphoma, Non-Hodgkin 2 Lymphoma, B-Cell 2 Lymphoma 2 Hematologic Neoplasms 2

Interventions

pembrolizumab 1 SH-1028 1 Injections 1 2-((5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-5-(2-hydroxy-3-morpholinopropyl)-3-methyl-5,6,7,8-tetrahydro-1H-pyrrolo(3,2-c)azepin-4-ketone 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07265921 2025-12-05

Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Recruiting

Advanced Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡